Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential

K E Greene, Kerry E. Greene, L. Michael Kettel, L M Kettel, Samuel S.C. Yen, S S Yen
Fertility and sterility · 1992 · vol. 58(2) , pp. 338–343 · doi:10.1016/s0015-0282(16)55200-5 · PMID:1633899 · W2189483992
Other OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This study investigated the potential contraceptive effects of interrupting endometrial maturation with an antiprogesterone during the early luteal phase, without altering hormonal profiles.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To examine hormonal and endometrial responses to intermittent low-dose RU486 administration in the luteal phase of the menstrual cycle. DESIGN: Prospective open trial in which subjects serve as their own controls. PATIENTS/PARTICIPANTS: Eight normal cycling women. INTERVENTIONS: RU486 (10 mg, orally) was administered 5 and 8 days after urinary luteinizing hormone (LH) surge of treatment cycle. MAIN OUTCOME MEASURES: Daily serum concentrations of LH, follicle-stimulating hormone, estradiol (E2), and progesterone (P) were determined in control, treatment, and recovery cycles (n = 5) or treatment and recovery cycles (n = 3). Changes in endometrial morphology and immunohistochemical staining for P receptor (PR) and E2 receptor (ER) were determined during control (or recovery) and treatment cycles. RESULTS: Cycle length and hormonal patterns were unaltered after treatment with RU486. As demonstrated by reduced stromal edema and delayed glandular development, endometrial dyssynchrony occurred in all eight treatment cycles. In addition, seven of eight treatment cycle endometria demonstrated a decrease in PR staining without consistent change in ER staining. CONCLUSIONS: Two low doses of RU486 given 72 hours apart during the luteal phase of the cycle disrupted ongoing endometrial maturation without altering the hormonal and time course of the menstrual cycle. This study provides a basis for the development of a novel form of luteal contraception.

My notes (saved in your browser only)

MeSH descriptors

Contraceptives, Oral Endometrium Luteal Phase Mifepristone Adult Contraceptives, Oral Endometrium Endometrium Endometrium Estradiol Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Immunoenzyme Techniques Luteinizing Hormone Luteinizing Hormone Mifepristone Mifepristone

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (27)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-13T18:37:28.025090+00:00
pubmed
last seen: 2026-10-08T21:03:30.943773+00:00
License: CC0 · commercial use OK